Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
941-960 of 1,307 trials

Atrial Fibrillation: IV Flecainide with Ranolazine

We are comparing the effectiveness of a combination of IV flecainide and oral ranolazine against IV flecainide alone for patients with recent onset atrial fibrillation. This study aims to find out which treatment better restores normal heart rhythm.

Atrial Fibrillation (AF)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyPediatrics

Ovarian Cancer: HIPEC Treatment Study

We are studying the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with standard care for ovarian cancer patients. This trial aims to see if HIPEC improves survival and quality of life compared to standard treatments alone.

Ovarian and Fallopian Tube CancerConfirmation phase (III)No PlaceboStandard MedicinesOncology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Lupus Nephritis: MSV-ALLO® Treatment Study

We are testing a new cell therapy for lupus nephritis to see if it helps patients achieve remission. The study compares this treatment to a placebo to evaluate its safety and effectiveness.

Lupus Nephritis3-6 monthsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesNephrologyRheumatology

Lichen Simplex Chronicus: Dupilumab Injections

We are studying whether dupilumab injections can help reduce itching in adults with Lichen Simplex Chronicus who haven't found relief from other treatments. The trial will also look at how this treatment affects sleep and overall quality of life.

Neurodermatitis6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementAllergologyDermatology

Chronic Spontaneous Urticaria: BP11 vs. Xolair

We are comparing a new treatment, BP11, to Xolair for patients with chronic spontaneous urticaria who haven't responded to antihistamines. The goal is to see if BP11 is as effective and safe as Xolair.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Chronic Low Back Pain: Melatonin Study

We are investigating whether melatonin can help reduce pain in patients with chronic low back pain. Participants will compare its effects to a placebo over six weeks.

Chronic Low Back Pain6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Ovarian Cancer: Rinatabart Sesutecan (Rina-S) Study

We are comparing a new treatment, Rina-S, to standard therapies for patients with platinum-resistant ovarian cancer. The goal is to see if Rina-S can help improve survival without disease progression.

Platinum-resistant Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Rectal Cancer: Ferumoxtran-10 MRI Study

We are testing a new MRI method to see if it better identifies lymph node involvement in patients with newly diagnosed rectal cancer. This may help doctors plan more effective treatments.

Rectal CancerMesorectal Lymph Node Metastases>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Preventing Abscesses After Appendicitis Surgery: ALPACA Trial

We are studying if a special antibiotic wash during surgery can lower the risk of abscesses in patients with complicated appendicitis. This trial aims to improve recovery and reduce complications after surgery.

Appendicitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesOrthopedics and Traumatology

Advanced Soft-Tissue Sarcomas: Next-Generation Sequencing Study

We are exploring whether high-throughput molecular analysis can help guide treatment for patients with advanced soft-tissue sarcomas. This study will compare treatment outcomes for those receiving NGS-guided therapy versus standard care.

Unresectable Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Gastric Cancer: IP Paclitaxel and Systemic Therapy Study

We are comparing the effects of intraperitoneal paclitaxel combined with standard therapy against standard therapy alone in patients with gastric cancer and peritoneal metastases. This study aims to see if the combination improves survival and quality of life.

Metastatic Gastric Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Type 1 Diabetes: Semaglutide Treatment Study

We are investigating whether adding semaglutide to standard treatment helps people with type 1 diabetes and 'double diabetes' better control their blood sugar and weight. This study will also look at insulin use and potential side effects.

Double Diabetes6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Emergency Tracheal Intubation: New Optimization Strategy

We are studying a new method for emergency tracheal intubation to see if it reduces complications in adult patients. This approach combines medication and ventilation techniques to improve patient safety during emergencies.

Respiratory Distress>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard Medicines

Preventing Pancreatic Fistulas: Botulinum Toxin Injection Study

We are studying whether botulinum toxin injections can help prevent complications after pancreatic surgery in patients undergoing distal pancreatectomy. This trial aims to improve recovery and reduce the risk of serious postoperative issues.

Pancreatic Fistula≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Myotonia Treatment: Mexiletine PR vs. Mexiletine IR

We are comparing two forms of mexiletine to see which one is safer and more effective for adults with non-dystrophic myotonias. This study aims to improve treatment options for conditions like myotonia congenita and paramyotonia congenita.

Myotonic DystrophyNon-Dystrophic Myotonias6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology